Illinois CancerCare, P.C. Partners with Canopy to expand patient access and care between visits. May 14, 2026 Canopy, the leader in Enterprise AI for oncology, today announced a partnership with Illinois CancerCare, P.C., one of the largest community oncology and hematology practices in Illinois with 14 clinic locations. Illinois CancerCare will deploy Canopy's comprehensive platform, including Remote Therapeutic Monitoring and oncology-specific AI for patient services. "Remote therapeutic monitoring is key to our value-based care initiatives such as the Enhancing Oncology Model, and it's also foundational for all of our patients on treatment - from adherence monitoring for oral oncolytics to expanding access to bispecific antibodies and CAR T-cell therapy. More broadly, we're investing in enterprise AI to modernize operations across our clinics, improving how patients communicate and engage with our care teams." - Michael Voeller, Executive Director of Illinois CancerCare, P.C. Canopy helps practices manage the growing complexity of cancer care by providing a unified AI platform across patient services: triage, call center and communications, front office, and pharmacy. By embedding AI and automation into existing workflows, Canopy enables faster issue resolution, reduces manual work, and helps practices capture sustainable reimbursement. Canopy recently introduced Kathy, an AI-powered phone operator built specifically for oncology and implemented across multiple practices. When call volumes peak and staff are busy, Kathy supports the team by verifying patients, identifying their intent, capturing key details, and escalating immediately when clinical needs arise. "Illinois CancerCare has built one of the country's leading independent oncology practices by continually investing in innovation and high-quality patient care. We're proud to partner with a team that shares our belief that AI should be thoughtfully developed to improve the care experience and outcomes for both patients and staff." - Lavi Kwiatkowsky, Founder and CEO of Canopy Studies demonstrating the potential impact of Canopy's platform on oncology patient experience in real-world settings have demonstrated: * 22% reduction in ER visits and hospitalizations per 100 patient months[1] * 52% reduction in infection-related hospitalizations in patients with hematologic malignancies, resulting in $977,695 in estimated annual savings per 1,000 patients[2] * 22% - 45% improvement in treatment persistence at three months[3] * 88% sustained patient engagement at six months[4] * Improved early detection of toxicities with bispecific antibody therapies[5] * Potential to improve adherence and manage toxicities associated with oral anticancer medication[6] Canopy serves ~10% of oncology providers in the U.S. and is rapidly growing. About Canopy Canopy is the leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network across 500+ sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.Canopycare. About Illinois CancerCare, P.C. Illinois CancerCare, P.C. is a comprehensive practice treating patients with cancer and blood diseases. The practice focuses on providing state-of-the-art treatments while staying on the leading edge of breakthrough research and medicines. Illinois CancerCare is one of the largest private oncology practices in the nation and has helped countless individuals overcome disease to live healthy, inspiring lives. Founded in 1977 by Dr. Stephen Cullinan in Peoria, Illinois, the practice has grown to include 21 physicians and 14 clinic locations. The care team also includes more than 30 nurse practitioners, 100+ nurses - over 50% of them certified as Oncology Certified Nurses (OCNs) - and more than 500 full- and part-time staff members. For more information, visit www.illinoiscancercare.com. Learn More Interested in learning more? Contact its team using the button below. Contact Us [1] Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508 [2] Essell J, Ascha M, Schaefer E, Calkins G, Kwiatkowsky L, Kolodziej M, Derman B. (December 6, 2025). Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy. Presented as an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. [3] Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528 [4] Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180 [5] Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting [6] Sharma, S., Doshi, G., Shumway, N., Schaefer, E., Dave, N., Marcus, A., Dyson, B., Derman, B., Essell, J., Ascha, M., Calkins, G., Neiman, J., Kwiatkowsky, L., & Kolodziej, M. (2025). Application of the remote therapeutic monitoring (RTM) platform to optimize adherence and manage toxicity of oral anti-cancer medications (OAM). JCO Oncology Practice, 21(suppl 10), abstract 594. DOI: 10.1200/OP.2025.21.10_suppl.594

USA Health partners with Canopy to operationalize ai-powered care and Remote Therapeutic Monitoring in academic oncology care. Canopy, the leader in Enterprise AI for oncology, today announced a partnership with the University of South Alabama (USA) Health Mitchell Cancer Institute, an academic research and treatment facility in Mobile, Alabama, to transform patient support between visits. USA Health selected Canopy's AI-native platform to replace legacy systems, aiming to extend the benefits of Remote Therapeutic Monitoring (RTM) across increasingly complex therapies while reducing operational burden for staff. "We're always looking for better ways to support our patients, especially when they're away from the clinic. Canopy's technology helps our staff stay connected with patients, identify issues earlier, and automate routine tasks so they can spend more time on what matters most." - Theresa McLaughlin, Administrative Director for Mitchell Cancer Institute Canopy helps cancer centers manage the growing complexity of care by providing a unified AI platform across patient services: triage, call center, front office, referrals, and pharmacy. By embedding AI and automation into existing workflows, Canopy enables faster issue resolution, reduces manual work, and helps practices capture sustainable reimbursement. "We're proud to partner with USA Health as they bring innovative therapies to patients. Our goal is to help deliver on the promise of those therapies while empowering their team with Enterprise AI tools purpose-built for oncology." - Lavi Kwiatkowsky, Founder and CEO of Canopy Studies demonstrating the potential impact of Canopy's platform on oncology patient experience in real-world settings have demonstrated: * 22% reduction in ER visits and hospitalizations per 100 patient months[1] * 22% - 45% improvement in treatment persistence at three months[2] * 88% sustained patient engagement at six months[3] * 52% reduction in infection-related hospitalizations in patients with hematologic malignancies, resulting in $977,695 in estimated annual savings per 1,000 patients[4] * Improved early detection of toxicities with bispecific antibody therapies[5] * Potential to improve adherence and manage toxicities associated with oral anticancer medication[6] USA Health Mitchell Cancer Institute is the first academic cancer center to join Canopy's rapidly growing network of 500+ unique sites of care. About Canopy Canopy is the leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network of more than 2,000 oncology providers across 500+ sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.Canopycare. About the University of South Alabama Health Mitchell Cancer Institute As part of the University of South Alabama Health, the Mitchell Cancer Institute (MCI) is the only academic cancer research and treatment facility on the upper Gulf Coast corridor. With more than 250 employees, including clinicians and basic researchers, MCI embraces its mission to vanquish cancer through transformative research, education, and health care. To learn more, visit www.usahealthsystem.com/mci. Learn More Interested in learning more? Contact its team using the button below. Contact Us [1] Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508 [2] Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528 [3] Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180 [4] Essell J, Ascha M, Schaefer E, Calkins G, Kwiatkowsky L, Kolodziej M, Derman B. (December 6, 2025). Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy. Presented as an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. [5] Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting [6] Sharma, S., Doshi, G., Shumway, N., Schaefer, E., Dave, N., Marcus, A., Dyson, B., Derman, B., Essell, J., Ascha, M., Calkins, G., Neiman, J., Kwiatkowsky, L., & Kolodziej, M. (2025). Application of the remote therapeutic monitoring (RTM) platform to optimize adherence and manage toxicity of oral anti-cancer medications (OAM). JCO Oncology Practice, 21(suppl 10), abstract 594. DOI: 10.1200/OP.2025.21.10_suppl.594

Utah Cancer Specialists partners with Canopy for Remote Therapeutic Monitoring and Enterprise AI. Canopy, the leader in Enterprise AI for oncology, today announced a partnership with Utah Cancer Specialists (UCS), the largest community-based oncology and hematology practice in Utah and a member of the ONCare Alliance, to modernize how care teams support patients between visits. UCS selected Canopy to replace legacy systems with an AI-native solution that keeps pace with the needs of their patients and staff while building scalable programs for Remote Therapeutic Monitoring (RTM) and Care Management (CCM/PCM). "It's important that our patients stay closely connected to the care teams who know them best. Canopy enables us to make care more patient-centric and reduce the administrative work that stands in the way." - Kyle Kitchen, Chief Clinical Officer at Utah Cancer Specialists Canopy helps practices manage the growing complexity of cancer care by providing a unified AI platform across patient services: triage, call center, front office, referrals, and pharmacy. By embedding AI and automation into existing workflows, Canopy enables faster issue resolution, reduces manual work, and helps practices capture sustainable reimbursement. "AI has a real role to play in supporting oncology clinicians, but only if it fits the way they operate. Innovation can't be a check-the-box exercise - practices need technology that keeps evolving with them. That's the commitment we're proud to bring to UCS." - Lavi Kwiatkowsky, Founder and CEO of Canopy Studies demonstrating the potential impact of Canopy's platform on oncology patient experience in real-world settings have demonstrated: * 22% reduction in ER visits and hospitalizations per 100 patient months[1] * 52% reduction in infection-related hospitalizations[2] * $977,695 in estimated annual savings per 1,000 patients with infection-related events[2] * 22% - 45% improvement in treatment persistence at three months[3] * 88% sustained patient engagement at six months[4] * Improved early detection of toxicities with bispecific antibody therapies[5] Care teams using Canopy have also seen: * 15-minute average resolution time for patient symptom reports[6] * 93% faster resolution of all patient requests compared to prior workflows[6] Canopy is contracted with 10% of oncology providers in the U.S. and rapidly growing. About Canopy Canopy is the leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network of more than 2,000 oncology providers across 500+ sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.Canopycare. About Utah Cancer Specialists Utah Cancer Specialists is the largest community-based oncology and hematology practice in Utah, with physicians providing medical oncology, hematology, radiation oncology, and imaging services. Its cancer specialists have expertise in every type of cancer, including rare malignancies, and actively participate in clinical research. One of its greatest strengths is its ability to translate today's most promising laboratory findings into tomorrow's new, more effective and less traumatic treatments. For more information, visit https://utahcancer.com/. Learn More Interested in learning more? Contact its team using the button below. Contact Us [1] Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508 [2] Essell J, Ascha M, Schaefer E, Calkins G, Kwiatkowsky L, Kolodziej M, Derman B. (December 6, 2025). Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy. Presented as an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. [3] Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528 [4] Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180 [5] Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting [6] Canopy internal analysis of partnership data